| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.88 [0.77, 1.01] | | < 1 | | 34% | 3 studies (3/-) | 96.1 % | low | not evaluable | high | crucial | - |
| progression or deaths (PFS) | 0.96 [0.57, 1.61] | | < 1 | | 95% | 3 studies (3/-) | 56.2 % | low | not evaluable | high | important | - |
| DCR | 0.60 [0.39, 0.94] | | > 1 | | 0% | 1 study (1/-) | 1.3 % | NA | not evaluable | | non important | - |
| events or deaths (EFS) | 0.63 [0.43, 0.93] | | < 1 | | 0% | 1 study (1/-) | 99.1 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 0.69 [0.20, 2.40] | | > 1 | | 96% | 3 studies (3/-) | 28.2 % | low | not evaluable | high | non important | - |
| pCR | 13.60 [6.77, 27.33] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 1.02 [0.35, 2.95] | | < 1 | | 1% | 2 studies (2/-) | 48.8 % | low | not evaluable | high | non important | - |
| AE (grade 3-4) | 1.31 [1.05, 1.63] | | < 1 | | 0% | 2 studies (2/-) | 0.8 % | low | not evaluable | high | non important | - |
| SAE (any grade) | 0.99 [0.66, 1.48] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.78 [0.17, 3.68] | | < 1 | | 56% | 2 studies (2/-) | 62.2 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 0.74 [0.33, 1.66] | | < 1 | | 95% | 3 studies (3/-) | 77.0 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 1.06 [0.46, 2.44] | | < 1 | | 0% | 3 studies (3/-) | 44.5 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 1.72 [0.89, 3.31] | | < 1 | | 52% | 2 studies (2/-) | 5.4 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.94 [0.06, 15.18] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 5.06 [0.57, 44.81] | | < 1 | | 0% | 2 studies (2/-) | 7.4 % | low | not evaluable | high | non important | - |
| Alopecia TRAE (grade 3-4) | 0.86 [0.41, 1.80] | | < 1 | | 0% | 3 studies (3/-) | 65.4 % | low | not evaluable | high | non important | - |
| Anaemia TRAE (grade 3-4) | 1.03 [0.65, 1.65] | | < 1 | | 60% | 3 studies (3/-) | 44.8 % | low | not evaluable | high | non important | - |
| Asthenia TRAE (grade 3-4) | 1.37 [0.69, 2.72] | | < 1 | | 0% | 2 studies (2/-) | 18.6 % | low | not evaluable | high | non important | - |
| Colitis TRAE (grade 3-4) | 2.01 [0.43, 9.46] | | < 1 | | 0% | 3 studies (3/-) | 18.9 % | low | not evaluable | high | non important | - |
| Constipation TRAE (grade 3-4) | 0.48 [0.04, 6.30] | | < 1 | | 0% | 2 studies (2/-) | 70.9 % | some concern | not evaluable | moderate | non important | - |
| Cough TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 2.02 [0.34, 12.03] | | < 1 | | 0% | 2 studies (2/-) | 22.2 % | low | not evaluable | high | non important | - |
| Diabetes TRAE (grade 3-4) | 1.32 [0.17, 10.43] | | < 1 | | 0% | 2 studies (2/-) | 39.8 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.69 [0.10, 4.85] | | < 1 | | 78% | 2 studies (2/-) | 64.5 % | low | not evaluable | high | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.50 [0.01, 25.13] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 1.51 [0.84, 2.72] | | < 1 | | 0% | 3 studies (3/-) | 8.6 % | low | not evaluable | high | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.31 [0.01, 6.85] | | < 1 | | 79% | 2 studies (2/-) | 76.6 % | low | not evaluable | high | non important | - |
| Headache TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 9.06 [0.52, 156.66] | | < 1 | | 0% | 1 study (1/-) | 6.7 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.31 [0.18, 9.44] | | < 1 | | 0% | 3 studies (3/-) | 39.6 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 8.04 [0.46, 140.38] | | < 1 | | 0% | 1 study (1/-) | 7.9 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 2.29 [0.37, 14.11] | | < 1 | | 0% | 3 studies (3/-) | 18.8 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 3.49 [0.75, 16.21] | | < 1 | | 45% | 2 studies (2/-) | 5.6 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.69 [1.05, 2.73] | | < 1 | | 0% | 3 studies (3/-) | 1.6 % | low | not evaluable | high | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 2.53 [0.86, 7.45] | | < 1 | | 0% | 1 study (1/-) | 4.6 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.78 [0.61, 1.00] | | < 1 | | 8% | 3 studies (3/-) | 97.5 % | low | not evaluable | high | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Myocarditis TRAE (grade 3-4) | 1.99 [0.09, 44.34] | | < 1 | | 0% | 1 study (1/-) | 33.3 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 2.32 [0.21, 25.15] | | < 1 | | 0% | 2 studies (2/-) | 24.6 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 1.77 [0.85, 3.67] | | < 1 | | 0% | 3 studies (3/-) | 6.4 % | low | not evaluable | high | non important | - |
| Nephritis TRAE (grade 3-4) | 3.49 [0.34, 35.41] | | < 1 | | 0% | 2 studies (2/-) | 14.7 % | low | not evaluable | high | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.81 [0.42, 1.55] | | < 1 | | 83% | 3 studies (3/-) | 74.1 % | low | not evaluable | high | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.13 [0.02, 1.08] | | < 1 | | 0% | 1 study (1/-) | 97.0 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 4.00 [0.21, 75.85] | | < 1 | | 0% | 1 study (1/-) | 18.1 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.24 [0.01, 5.23] | | < 1 | | 0% | 1 study (1/-) | 81.7 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 1.88 [0.62, 5.72] | | < 1 | | 0% | 1 study (1/-) | 13.2 % | NA | not evaluable | | non important | - |
| Peripheral sensory neuropathy TRAE (grade 3-4) | 0.72 [0.13, 4.06] | | < 1 | | 37% | 2 studies (2/-) | 64.7 % | low | not evaluable | high | non important | - |
| Pneumonia TRAE (grade 3-4) | 0.24 [0.01, 5.23] | | < 1 | | 0% | 1 study (1/-) | 81.7 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 3.15 [0.68, 14.57] | | < 1 | | 0% | 3 studies (3/-) | 7.2 % | low | not evaluable | high | non important | - |
| Pruritus TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Pyrexia TRAE (grade 3-4) | 2.39 [0.45, 12.62] | | < 1 | | 0% | 2 studies (2/-) | 15.4 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 3.51 [0.43, 28.62] | | < 1 | | 0% | 1 study (1/-) | 12.2 % | NA | not evaluable | | non important | - |
| Sarcoidosis TRAE (grade 3-4) | 0.50 [0.01, 25.13] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
| Sepsis TRAE (grade 3-4) | 0.94 [0.02, 47.78] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 7.26 [1.88, 28.05] | | < 1 | | 0% | 3 studies (3/-) | 0.2 % | low | not evaluable | high | non important | - |
| Stomatitis TRAE (grade 3-4) | 2.64 [0.12, 57.65] | | < 1 | | 49% | 2 studies (2/-) | 27.1 % | low | not evaluable | high | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.94 [0.06, 15.18] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.50 [0.13, 17.05] | | < 1 | | 0% | 2 studies (2/-) | 37.4 % | low | not evaluable | high | non important | - |
| Urticaria TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Uveitis TRAE (grade 3-4) | 0.50 [0.01, 25.13] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 1.51 [0.59, 3.82] | | < 1 | | 0% | 1 study (1/-) | 19.5 % | NA | not evaluable | | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.47 [0.04, 5.22] | | < 1 | | 0% | 1 study (1/-) | 72.9 % | NA | not evaluable | | non important | - |
